Skip to main content
amavitaRESEARCH
All trials
Phase 1Heart FailureEnrolling Soon

Phase 1 HFpEF — VS-041

HFpEF

About this study

First-in-human evaluation of VS-041, a novel mechanism targeting cardiac structural remodeling in heart failure with preserved ejection fraction.

Sponsor: VASA Therapeutics

Key eligibility

  • Adults 40–80 with NYHA Class II–III HFpEF
  • LVEF ≥ 50%
  • Elevated NT-proBNP

Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.

What participation involves

Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.

Read: What to expect as a patient

Note

This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.